Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies. In the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment of pancreatic insulinoma.
Patients (P): Alla patients referred to Sahlgrenska University Hospital for the diagnostic work-up and management of a suspected pancreatic insulinoma. Intervention (I): EUS-RFA Control group (C): Patients with insulinoma treated with conventional surgery during the time frame 2018-2025 (historic controls). Outcome (O): * Technical feasibility * Patient safety * Clinical efficacy (follow-up with biochemistry and imaging at 3, 6, 12, and 24 months post-EUS-RFA).
Study Type
OBSERVATIONAL
Enrollment
20
Treatment of insulinoma by EUS-RFA
Sahlgrenska Univeristy Hospital
Gothenburg, Sweden
RECRUITINGClinical efficacy
Symptom-free survival after EUS-RFA (no clinical signs of residual disease, i.e. insulin-producing insulinoma cells)
Time frame: 3-24 months post-EUS
Patient safety
Adverse evnt rate according to Clavien-Dindo at 30 days post-EUS-RFA
Time frame: 30 days post-EUS-RFA
Imaging effect post-EUS-RFA with respect to tumor size
Imaging of the insulinoma by EUS post-EUS-RFA and thereby the assessment of tumor size
Time frame: 3-24 months post-EUS-RFA
Imaging effect post-EUS-RFA with respect to tumor vascularization
Imaging of the insulinoma by EUS post-EUS-RFA and thereby the assessment of remaining tumor vascularization
Time frame: 3-24 months post EUS-RFA
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.